CoChat

Tight Long-term Dynamic Doxycycline Responsive Nigrostriatal GDNF Using a Single rAAV Vector

Open access
Manfredsson, Fredric P, Burger, Corinna, Rising, Aaron C, Zuobi-Hasona, Kheir, Sullivan, Layla F, Lewin, Alfred S, Huang, Julia, Piercefield, Emily, Muzyczka, Nicholas, Mandel, Ronald J · 2009 · Molecular Therapy
Cited by 67

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Glial cell line-derived neurotrophic factor (GDNF) gene transfer is being developed as a treatment for Parkinson's disease (PD). Due to the potential for side effects, external transgene regulation should enhance this strategy's safety profile. Here, we demonstrate dynamic control during long-term expression of GDNF using a recombinant adeno-associated virus (rAAV)-based bicistronic tetracycline (tet)-off construct. Nigrostriatal GDNF overexpression induces body weight alterations in rodents, enabling longitudinal in vivo tracking of GDNF expression after nigral vector delivery. Regulated GDNF expression was highly sensitive to dietary doxycycline (DOX), displaying undetectable striatal GDNF levels at serum DOX levels below those required for antimicrobial activity. However, in the absence of DOX, striatal GDNF levels exceeded levels required for efficacy in PD models. We also demonstrate the absence of a series of known GDNF-associated side effects when using direct intrastriatal vector delivery. Therefore, this single rAAV vector system meets most of the requirements for an experimental reagent for treatment of PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2009.196

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Peterson, 2008, Treatment of Parkinson's disease with trophic factors, Neurotherapeutics, 5, 270, 10.1016/j.nurt.2008.02.003 · DOI · Paper page
  2. Bespalov, 2007, GDNF family receptor complexes are emerging drug targets, Trends Pharmacol Sci, 28, 68, 10.1016/j.tips.2006.12.005 · DOI · Paper page
  3. Pascual, 2008, Absolute requirement of GDNF for adult catecholaminergic neuron survival, Nat Neurosci, 11, 755, 10.1038/nn.2136 · DOI · Paper page
  4. Ibanez, 2008, Catecholaminergic neuron survival: getting hooked on GDNF, Nat Neurosci, 11, 735, 10.1038/nn0708-735 · DOI
  5. Walker, 1998, Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease, Brain Res, 792, 207, 10.1016/S0006-8993(98)00131-0 · DOI
  6. Bartus, 2007, Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point, Parkinsonism Relat Disord, 13, S469, 10.1016/S1353-8020(08)70052-X · DOI
  7. Mandel, 2006, Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders, Mol Ther, 13, 463, 10.1016/j.ymthe.2005.11.009 · DOI · Paper page
  8. Björklund, 2000, Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model, Brain Res, 886, 82, 10.1016/S0006-8993(00)02915-2 · DOI · Paper page
  9. Kordower, 1999, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease, Ann Neurol, 46, 419, 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q · doi:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q
  10. Kordower, 2008, Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself, Exp Neurol, 209, 34, 10.1016/j.expneurol.2007.08.001 · DOI
  11. Cress, 2008, The need for regulatable vectors for gene therapy for Parkinson's disease, Exp Neurol, 209, 30, 10.1016/j.expneurol.2007.08.015 · doi:10.1016/j.expneurol.2007.08.015
  12. Georgievska, 2004, Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector, Hum Gene Ther, 15, 934, 10.1089/hum.2004.15.934 · DOI · Paper page
  13. Chtarto, 2003, Tetracycline-inducible transgene expression mediated by a single AAV vector, Gene Ther, 10, 84, 10.1038/sj.gt.3301838 · DOI · Paper page
  14. Szulc, 2008, Conditional gene expression and knockdown using lentivirus vectors encoding shRNA, Methods Mol Biol, 434, 291
  15. Georgievska, 2002, Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer, Exp Neurol, 177, 461, 10.1006/exnr.2002.8006 · DOI · Paper page
  16. Rosenblad, 2003, Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system, Eur J Neurosci, 17, 260, 10.1046/j.1460-9568.2003.02456.x · DOI · Paper page
  17. Georgievska, 2004, Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system, J Neurosci, 24, 6437, 10.1523/JNEUROSCI.1122-04.2004 · DOI · Paper page
  18. Sajadi, 2005, Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production, J Neurochem, 93, 1482, 10.1111/j.1471-4159.2005.03139.x · DOI
  19. Manfredsson, 2009, Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity, Mol Ther, 17, 980, 10.1038/mt.2009.45 · DOI · Paper page
  20. Hovland, 2007, Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys, Toxicol Pathol, 35, 1013, 10.1177/01926230701481899 · DOI · Paper page
  21. Szulc, 2006, A versatile tool for conditional gene expression and knockdown, Nat Methods, 3, 109, 10.1038/nmeth846 · DOI · Paper page
  22. Fitzsimons, 2002, Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain, Methods, 28, 227, 10.1016/S1046-2023(02)00227-X · DOI
  23. Goverdhana, 2005, Regulatable gene expression systems for gene therapy applications: progress and future challenges, Mol Ther, 12, 189, 10.1016/j.ymthe.2005.03.022 · DOI · Paper page
  24. Ye, 1999, Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer, Science, 283, 88, 10.1126/science.283.5398.88 · DOI · Paper page
  25. Chang, 2008, Molecular, cellular, and behavioral characterization of a tetracycline (Tet)-regulated rAAV vector for human aromatic amino acid decarboxylase (hAADC) in a rat model of Parkinson's disease (PD), Mol Ther, 16, S264, 10.1016/S1525-0016(16)40109-7 · doi:10.1016/s1525-0016(16)40109-7
  26. Baron, 1997, Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential, Nucleic Acids Res, 25, 2723, 10.1093/nar/25.14.2723 · DOI · Paper page
  27. Lowenstein, 2002, Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective, Trends Immunol, 23, 23, 10.1016/S1471-4906(01)02063-4 · DOI
  28. Xiong, 2008, Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain, Mol Ther, 16, 343, 10.1038/sj.mt.6300375 · DOI
  29. Gill, 1988, Negative effect of the transcriptional activator GAL4, Nature, 334, 721, 10.1038/334721a0 · DOI · Paper page
  30. Yueh, 2000, Herpes simplex virus transcriptional activator VP16 is detrimental to preimplantation development in mice, Mol Reprod Dev, 55, 37, 10.1002/(SICI)1098-2795(200001)55:1<37::AID-MRD6>3.0.CO;2-N · doi:10.1002/(sici)1098-2795(200001)55:1<37::aid-mrd6>3.0.co;2-n
  31. Shockett, 1996, Diverse strategies for tetracycline-regulated inducible gene expression, Proc Natl Acad Sci USA, 93, 5173, 10.1073/pnas.93.11.5173 · DOI
  32. Cunha, 1982, Doxycycline, Ther Drug Monit, 4, 115, 10.1097/00007691-198206000-00001 · DOI · Paper page
  33. Stieger, 2009, In vivo gene regulation using tetracycline-regulatable systems, Adv Drug Deliv Rev, 61, 527, 10.1016/j.addr.2008.12.016 · DOI
  34. Berman, 2007, Update on rosacea and anti-inflammatory-dose doxycycline, Drugs Today, 43, 27, 10.1358/dot.2007.43.1.1025697 · DOI
  35. Tatarewicz, 2007, Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion, J Clin Immunol, 27, 620, 10.1007/s10875-007-9117-8 · DOI
  36. Burger, 2005, Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion, Mol Ther, 11, 327, 10.1016/j.ymthe.2004.08.031 · DOI · Paper page
  37. Manfredsson, 2007, rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease, Exp Neurol, 207, 289, 10.1016/j.expneurol.2007.06.019 · DOI
  38. Liu, 2008, Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea, Mol Ther, 16, 474, 10.1038/sj.mt.6300379 · DOI
  39. Zolotukhin, 2002, Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors, Methods, 28, 158, 10.1016/S1046-2023(02)00220-7 · DOI · Paper page
  40. Tümer, 2006, Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity, Neurobiol Aging, 27, 459, 10.1016/j.neurobiolaging.2005.03.018 · DOI
  41. Ruz, 2004, Rapid and simple determination of doxycycline in serum by high-performance liquid chromatography. Application to particulate drug delivery systems, J Chromatogr A, 1031, 295, 10.1016/j.chroma.2003.12.028 · DOI

Cited by

See all 67

Metadata

Authors
Manfredsson, F. P., Burger, C., Rising, A. C., Zuobi-Hasona, K., Sullivan, L. F., Lewin, A. S., Huang, J., Piercefield, E., Muzyczka, N., & Mandel, R. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2009-11
Volume
17
Issue
11
Pages
1857-1867
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2127129865
Cited by
67
References
7
FWCI
3.92
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.